secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K/A
Filed at:   2022-11-15T23:59:59+00:00
Accession:  0001493152-22-032353
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech amends Q3 2022 8-K to correct CellerateRX facility count from 1,593 to 1,714
--------------------------------------------------------------------------------

- Original filing reported CellerateRX approved in 1,593 facilities as of Sep 30, 2022.
- Acquisition of Scendia Biologics added 121 facilities, bringing corrected total to 1,714.
- Amendment only revises this specific number; all other disclosures remain unchanged.
- No change to financial results or any other operational metrics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315222032353/0001493152-22-032353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315222032353/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-032353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer